A novel mutant allele of the CYP2A6 gene (CYP2A6* 11) found in a cancer patient who showed poor metabolic phenotype towards tegafur

Pharmacogenetics

Volumn 12, Issue 4, 2002, Pages 299-306

  Daigo, Satoshi ^a   Takahashi, Yoshiki ^a   Fujieda, Masaki ^a   Ariyoshi, Noritaka ^a   Yamazaki, Hiroshi ^a   Koizumi, Wasaburo ^a   Tanabe, Satoshi ^a   Saigenji, Katsunori ^a   Nagayama, Sekio ^a   Ikeda, Kazumasa ^a   Nishioka, Yasuhiko ^a   Kamataki, Tetsuya ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Cancer; Genetic polymorphism; Whole deletion

Indexed keywords

CYTOCHROME P450 2A6; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; TEGAFUR; ANTINEOPLASTIC ANTIMETABOLITE; COUMARIN; COUMARIN 7 HYDROXYLASE; COUMARIN 7-HYDROXYLASE; COUMARIN DERIVATIVE; DNA; GIMERACIL; MIXED FUNCTION OXIDASE; OXONIC ACID; PRIMER DNA; PYRIDINE DERIVATIVE; RECOMBINANT PROTEIN; S 1 (COMBINATION); UNSPECIFIC MONOOXYGENASE;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CATALYSIS; CLINICAL ARTICLE; DRUG EFFECT; ENZYME SUBSTRATE; FEMALE; GENE DELETION; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LIVER MICROSOME; MALE; NUCLEOTIDE SEQUENCE; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; STOMACH CANCER; AREA UNDER THE CURVE; BLOOD; CHEMISTRY; DRUG COMBINATION; ENZYMOLOGY; ESCHERICHIA COLI; GENETIC TRANSFECTION; GENETICS; GENOTYPE; ISOLATION AND PURIFICATION; KINETICS; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; STOMACH TUMOR;

ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; COUMARINS; DNA PRIMERS; DNA, NEOPLASM; DRUG COMBINATIONS; ESCHERICHIA COLI; GENOTYPE; HUMAN; KINETICS; MIDDLE AGE; MIXED FUNCTION OXYGENASES; MUTAGENESIS, SITE-DIRECTED; OXONIC ACID; POLYMERASE CHAIN REACTION; POLYMORPHISM (GENETICS); PYRIDINES; RECOMBINANT PROTEINS; STOMACH NEOPLASMS; SUPPORT, NON-U.S. GOV'T; TEGAFUR; TRANSFECTION; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 0036016314     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200206000-00005     Document Type: Article

References (45)

1. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P450 2A6 in human liver microsomes in vitro
2. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes
3. In vitro metabolism of fadrozole (CGS 16949A) in human microsomes and human cell lines expressing a single P450 isozyme
4. Identification of the human liver cytochrome P450 responsible for coumarin 7-hydroxylase activity
5. cDNA and deduced amino acid sequences of human P450 IIA3 (CYP2A3)
6. Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes
7. Purification and characterization of human liver microsomal cytochrome P450 2A6
8. Human kidney methoxyflurane and sevoflurane metabolism. Intrarenal fluoride production as a possible mechanism of methoxyflurane nephrotoxicity
9. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-enevalproic acid
10. (+)-cis-3, 5-dimethyl-2-(3-pyridyl) thiazolidin-4-one hydrochloride (SM-12502) as a novel substrate for cytochrome P450 2A6 in human liver microsomes
11. Role of human cytochrome P450 2A6 in C-oxidation of nicotine
12. Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes
13. A tobacco smoke-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6
14. 1
15. Comparison of a novel thin-layer chromatographic-fluorescence detection method with a spectrofluorometric method for the determination of 7-hydroxycoumarin in human urine
16. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers
17. Interindividual variability of coumarin 7-hydroxylation in a Turkish population
18. The CYP2A gene subfamily: Species differences, regulation, catalytic activities and role in chemical carcinogenesis
19. Antitumor activity of 1 M tegafur - 0.4 M 5-chloro-2, 4-dihydroxypyridine - 1 M potassium oxonate (S-1) against human colon carcinoma orhotopically implanted into nude rats
20. Putative role of dihydropyrimidine dehydrogenase in the toxic side effect of 5-fluorouracil in colorectal cancer patients
21. Cytochrome P450-dependent oxidative cleavage of 1-(tetrahydro-2-furanyl)-5-fluorouracil to 5-fluorouracil
22. Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydroxypyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography-negative ion chemical ionization mass spectrometry
23. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6* 1B) apparently diagnosed as heterozygotes for CYP2A6* 1A and CYP2A6* 4C
24. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli
25. Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification and reconstitution of catalytic activity
26. The carbon monoxide-binding pigment of liver microsomes
27. Hepatic triphosphopyridine nucleotide-cytochrome c reductase: Isolation, characterization and kinetic studies
28. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes
29. A genetic polymorphism in coumarin 7-hydroxylation: Sequence of the human CYP2A genes and identification of variant CYP2A6 alleles
30. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase
31. Identification and characterisation of novel polymorphisms in the CYP2A locus: Implications for nicotine metabolism
32. Genetic polymorphism of CYP2A6 in the German population
33. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis -3, 5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502)
34. Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype
35. A new CYP2A6 gene deletion responsible for the in vivo polymorphic metabolism of (+)-cis -3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride in humans
36. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population
37. CYP2A6 gene deletion reduces susceptibility to lung cancer
38. Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences
39. Molecular modelling of members of the P4502A subfamily: Application to studies of enzyme specificity
40. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians
41. Studies of the metabolism of diethyl p-nitrophenol phosphothionate (parathion) and benzphetamine using an apparently homogeneous preparation of rat liver cytochrome P450: Effect of a cytochrome P450 antibody preparation
42. Expression of cytochrome P450 2A6 in Escherichia coli: Purification, spectral and catalytic characterization, and preparation of polyclonal antibodies
43. Purified liver microsomal NADPH-cytochrome P450 reductase
44. Identification of retained N-formylmethionine in bacterial recombinant mammalian cytochrome P450 proteins with the N-terminal sequence MALLLAVFL: Roles of residues 3-5 in retention and membrane topology